Objectives: To analyse immunological changes during treatment with a monoclonal anti-tumour necrosis factor a (TNFa) antibody, infliximab, in patients with rheumatoid arthritis (RA). Methods: 25 patients with RA and 5 patients with other arthritides were studied during the first 6 weeks of treatment with infliximab. At the start of treatment and after 2 and 6 weeks, spontaneous expression of CCR3 and CCR5 on peripheral blood T cells and monocytes was studied by flow cytometry. 
T he inflamed synovium of patients with rheumatoid arthritis (RA) is characterised by massive leucocytic infiltration, mainly consisting of macrophages, T lymphocytes, and plasma cells. These cells express many proinflammatory cytokines, chemokines, and growth factors and are considered responsible for the degradation of the cartilage and erosion of juxta-articular bone. 1 2 Tumour necrosis factor a (TNFa) is expressed mainly by cells of the macrophage/monocyte lineage and is the most abundant and rapidly produced 3 proinflammatory cytokine in the rheumatoid joint. It has a central role in regulation of the synthesis and function of proinflammatory molecules and is involved in the recruitment of immune cells infiltrating into the joints. 4 Treatment with agents blocking the function of TNFa has proved to be highly effective in RA. To date there are two blocking agents in clinical use, a soluble TNFa receptor, etanercept, and a monoclonal antibody, infliximab. 5 6 The mechanisms behind the clinical effect of TNFa blocking treatment are not fully understood. TNFa blocking by antibodies or soluble receptors reduces the expression of vascular adhesion molecules 7 and inhibits the spontaneous production of interleukin (IL)1 and IL6 in an animal model. 8 Within days after starting infliximab treatment serum IL6 levels fall to normal and C reactive protein (CRP), primarily controlled by IL6, normalises. 9 10 In patients with RA also an increase in the production of interferon c (IFNc) by lymphocytes has been reported after treatment with soluble TNFa receptor. 11 At the same time, reduction in the homing of lymphocytes to the joints is seen.
TNFa also participates in the formation of new blood vessels in the rheumatoid joint. This not only enables enhanced delivery of inflammatory cells and mediators to the joint but also creates an invasive property of pannus at the cartilage and bone junction. Blocking of TNFa reduces the raised concentrations of serum vascular endothelial growth factor 12 detected in patients with RA and reduces angiogenesis. However, the immediate immunological mechanisms resulting from the blocking of TNFa are crucial because clinical improvement is seen in days after the start of treatment.
To study the mechanisms in the TNFa blockade we examined the expression of chemokine receptors (CCR3, CCR5), and the secretion of IL4, IL5, IFNc, and TNFa in peripheral blood T cells and monocytes of patients with active RA or other arthritides during early treatment with infliximab. The mRNA expression of IFNc, IL4, IL5, and TNFa in peripheral blood mononuclear cells (PBMC) was assessed with real time reverse transcriptase-polymerase chain reaction (RT-PCR). We also followed the changes in plasma levels of acute phase reactants, such as CRP, serum amyloid protein A (SAA), rheumatoid factor (RF), antifilaggrin antibodies (AFA), and antibodies to filaggrin derived cyclic citrullinated peptide (aCCP).
PATIENTS AND METHODS

Patients
We studied 25 patients with active RA who had not responded to conventional treatment with disease modifying antirheumatic drugs (DMARDs), including methotrexate, and five patients with other chronic active joint diseases (two patients with psoriatic arthritis, one with chronic reactive arthritis, one with spondyloarthropathy, and one with juvenile idiopathic arthritis) in whom treatment with infliximab was started. At the time of examination, all patients were using varying antirheumatic drugs either as a single DMARD or in different combinations. Twenty one patients with RA and four patients with other arthritides were receiving low dose (,10 mg/day) prednisone. Table 1 presents the characteristics of the patients.
In the patients with RA the response to infliximab was evaluated at week 2 by calculating the American College of Rheumatology (ACR) response 13 (in two patients the information was available only at week 6). Patients with an improvement of at least 20% (ACR20) were considered to be responders. Fifteen patients with RA were considered to be responders, 10 non-responders.
Nine healthy people matched for age and sex were studied as controls.
Cell extraction EDTA-blood was collected from the patients immediately before the infusions of infliximab (3 mg/kg) at the start and at 2 and 6 weeks during the treatment. EDTA-blood was taken at 2 week intervals from healthy controls.
PBMC were isolated by Ficoll gradient centrifugation. The cells were then washed three times with pyrogen free phosphate buffered saline (PBS) and suspended in a concentration of 2610 6 cells/ml in RPMI medium containing 5% AB serum, 25 mM Hepes, 2 mM glutamine, and 25 mg/ml gentamicin.
Fluorescence activated cell sorter (FACS) for chemokine receptor analysis PerCP conjugated antihuman CD3, FITC conjugated antihuman CD8 and CD14, and PE conjugated antihuman IFNc and IL4 antibodies and isotype control and leucogate were purchased from Becton Dickinson (BD, Erembodegem, Belgium). PE conjugated antihuman CCR3 and CCR5 antibodies were purchased from R&D (Abingdon, UK).
Ex vivo PB derived cells were washed with PBS containing 0.5% bovine serum albumin (PBS-BSA) and resuspended in 1 ml of PBS-BSA. To detect CD3, CD8, CD14, CCR3, and CCR5, 2610 5 cells were incubated for 20 minutes in the dark with 5 ml of each labelled monoclonal antibody. The cells were then washed once with PBS-BSA and suspended in FACS Flow solution for analysis.
Stained cells (20 000) were gated by side scatter and fluorochrome parameters for the T cell (CD3 perCP) and monocyte (CD14 FITC) analyses (FACS Calibur, BD). CD3 gated CD8 negative T cells were considered as CD4 cells.
The results were expressed as the percentage of cells staining positive for different markers. The cut off point for positive staining for intracellular cytokines and chemokine receptors is above the level of the control isotype antibody.
Cell stimulation
Ficoll isolated cells were stimulated in a concentration of 2610 5 cells in 200 ml volume with 5 mg/ml phytohaemagglutinin (PHA) for 24 hours in U bottomed plates at 37˚C. Supernatants and cells were collected 24 hours after the stimulation and analysed further.
Enzyme linked immunosorbent assay (ELISA) for IFNc, IL5, IL4, and TNFa For detection of IFNc, 96 well microtitre plates (Maxisorb, Nunc, Roskilde, Denmark) were coated with monoclonal antihuman IFNc antibody (clone 2G1; Endogen, Woburn, MA) at a concentration of 2 mg/ml (50 ml/well) and incubated overnight at 4˚C. After washing with PBS containing 0.05% Tween (PBS-T), the plates were blocked with 1% BSA in PBS for 30 minutes. Dilutions of recombinant human IFNc (catalogue No 19751N; Pharmingen, San Diego, CA) were used to create a standard curve. Supernatant samples and standards were incubated for 2 hours. After washing with PBS-T, biotinylated antihuman IFNc monoclonal antibody (clone B133.5; Endogen) was added at a concentration of 0.5 mg/ml (50 ml/well) and the plates were incubated for 1.5 hours. After washing with PBS-T, streptavidin-alkaline phosphatase complex (Zymed, San Francisco, CA) was added for 30 minutes' incubation. p-Nitrophenyl phosphate (Medix, Kauniainen, Finland) was used to develop the colour for reading at 405 nm. The concentration of IFNc secreted into the supernatants of unstimulated cells was subtracted from that of the stimulated cells. The detection level of the assay was 50 pg/ml.
Measurement of IL5 was performed according to the protocol used for IFNc. Purified rat antihuman IL5 (1 mg/ml; clone TRFK5, Pharmingen) was used as primary antibody and biotinylated rat antihuman IL5 (0.5 mg/ml; clone JES1-5A10, Pharmingen) as secondary antibody. Dilutions of recombinant human IL5 (catalogue No 19651V, Pharmingen) were used to create the standard curve. The detection level for IL5 was 30 pg/ml. IL4 was measured from the supernatants by PeliKine Compact human IL4 ELISA kit (catalogue No M1914; CLB, 
ELISA for antifilaggrin antibodies
The extraction and purification of filaggrin from human skin was effected and used as an antigen in an ELISA as previously described.
14 ELISA for aCCP Cyclic citrullinated peptide (CCP; cfc1-cyc), described by Schellekens et al, 15 was used as the antigen. The peptide was synthesised, cyclicised, and purified by high performance liquid chromatography at the Institute of Biotechnology, University of Helsinki (Dr C Kantor-Aaltonen).
CCP at a concentration of 1 mg/ml in 50 mM ammonium bicarbonate buffer, pH 9.6, was applied onto 96 well microtitre plates (100 ml/well; EXICON, Peptide immobiliser). The plates were incubated overnight at 4˚C. The wells were then emptied and washed three times with PBS-T. Human serum samples (100 ml), diluted 1:200 in PBS-T containing 0.2% human serum albumin (Finnish Red Cross Blood Transfusion Service, Helsinki, Finland), were then applied onto the plates and incubated at room temperature for 1.5 hours. After the incubation the wells were rinsed three times with PBS-T, and 100 ml of alkaline phosphatase conjugated rabbit antihuman IgG (Jackson Immunoresearch, West Grove Pa, USA) diluted 1:1000 in PBS-T was added and incubated for 1 hour at room temperature. After rinsing the wells three times with PBS-T, the substrate (p-nitrophenyl phosphate; Sigma, St Louis, Mo, USA), 1 mg/ ml in 50 mM carbonate buffer, pH 9.8, was added. The developed colour was read at 405 nm with an automated ELISA reader (Titertek Multiskan; Eflab, Helsinki, Finland) when a predetermined optical density level of reference RA sera was reached. The mean intra-assay variation of the method for a high positive serum was 6.4%, and for a low positive serum 5.9% (20 determinations). Interassay variation was 6% for a high positive serum and 14% for a low positive serum in seven successive tests.
Real time reverse transcriptase-polymerase chain reaction (RT-PCR)
The mRNA expression of cytokines and chemokine receptors was detected by real time RT-PCR from unstimulated and PHA stimulated cells.
Total RNA (tRNA) was extracted from frozen cells stored at 270˚C in the lysis buffer of RNA Total Gen Elute Mammalian RNA kit. The reverse transcription reaction was carried out in a final volume of 20 ml by using TaqMan Reverse Transcription Reagents (Applied Biosystems, Foster City, CA, USA). The solution was treated with 0.01 U/ml DNAase (Boehringer Mannheim) before adding the Multiscribe Reverse Transcriptase-enzyme (1.25 U/ml).
Real Time PCR was performed using an automated fluorometer, ABI Prism 7700 Sequence Detection System (Applied Biosystems), and TaqMan PDAR (pre-developed
) were used. Ribosomal 18S (catalogue No 4310893E) was used as endogenous control. The PCR reactions were run in triplicate wells with 5 ng of each cDNA. The expression of each cytokine was measured also from a home made calibrator sample, which was prepared from PHA stimulated PBMC of a healthy subject.
We used the comparative Ct method to measure the gene transcription in samples. The Ct of 18S was subtracted from the cytokine Ct. This difference was the DCt value. The DCt of the analysed sample was then subtracted from the DCt of the calibrator. This difference is called the DDCt value. The results are expressed as relative units based on calculation of 2 2DDCt , which gives the relative amount of cytokine normalised to endogenous control (18S) and compared with calibrator.
Statistics
A comparison of variables between the different follow up samples was carried out with the Wilcoxon signed ranks test. We used the Mann-Whitney test for comparison of two groups. A p value ,0.05 was considered significant.
RESULTS
Cytokine and chemokine receptor profile at entry At entry, patients with RA and patients with other arthritides showed a lower secretion of IFNc than controls (median 1513 v 11 970 pg/ml, p,0.0001 and median 3753 v 11 970 pg/ml, p = 0.004, for patients with RA and other arthritides, respectively; ranges were 0-18 700 pg/ml for RA, 0-7370 pg/ml for other arthritides, 6788-32 080 pg/ml for healthy controls). Also, the ratio of IFNc/IL4 mRNA of PHA stimulated PBMC was lower in RA and in other arthritides than in controls (median 0.2 v 1.7, p = 0.003 and median 0.0 v 1.7, p = 0.004, for patients with RA and other arthritides, respectively; ranges 0-13 for RA, 0-0.3 for other arthritides, 0-7 for healthy controls). Patients with RA also had a lower number of monocytes expressing CCR3 than controls (median 1 v 2.4, p = 0.009; ranges 0-5 for RA, 1-7 for healthy controls). Patients with other arthritides did not differ in the number of monocytes expressing CCR3 (data not shown).
In patients with other arthritides a lower expression of TNFa mRNA was noted than in controls (median 222 v 645, p = 0.003; ranges 0-338 for other arthritides, 270-1701 for healthy controls). Such a difference was not seen between controls and patients with RA (data not shown).
No differences between patient and control groups were seen in the number of T cells expressing CCR3 or CCR5, in the mitogen stimulated secretion of TNFa or IL4, or in the number of monocytes expressing CCR5.
Changes in autoantibodies and serum markers for inflammation during infliximab treatment
In patients with RA the plasma CRP and SAA levels had decreased by 2 weeks after the first TNFa infusion (median 45 v 6 mg/ml, range 5-272 mg/ml before treatment and 1-276 mg/ml 2 weeks after, p,0.0001 for CRP; and median 236 v 40 ng/ml, range 14.5-495 ng/ml before treatment and 4-473 ng/ml 2 weeks after, p,0.0001 for SAA) and were still significantly lower after 6 weeks' follow up when compared with the levels measured before treatment (median 45 v 7 mg/ ml, range 5-272 mg/ml before treatment and 1-93 mg/ml 6 weeks after, p,0.0001 for CRP; and median 236 v 30 ng/ml, range 14-495 ng/ml before treatment and 7-268 ng/ml 6 weeks after, p,0.0001 for SAA).
In patients with other arthritides the plasma CRP and SAA levels had decreased significantly by 2 weeks after the start of treatment (median 13 v 0 mg/ml, range 7-92 mg/ml before treatment and 0-5 mg/ml 2 weeks after, p = 0.043 for CRP; and median 243 v 11 ng/ml, range 20-303 ng/ml before treatment and 7-22 ng/ml 2 weeks after, p = 0.043 for SAA). The SAA levels were decreased also at the 6 week follow up point (median 243 v 11 ng/ml, range 20-303 ng/ml before treatment and 9-137 ng/ml 6 weeks after, p = 0.043).
No such changes were seen in healthy controls (data not shown).
The level of IgM RF in patients with RA had decreased by 2 weeks after the start of treatment (median 157 v 114 IU/ml, range 2.5-437 before treatment and 4-406 2 weeks after, p = 0.002).
The concentrations of IgG class AFA and CCP autoantibodies in the plasma were not affected by the infliximab treatment during 6 weeks' follow up in patients with RA (data not shown).
Cytokine profile during infliximab treatment
IFNc and IL4 secretion of PBMC, stimulated by PHA, increased in the patients with RA during the 6 week period of treatment (median 1513 v 14 190 pg/ml, p,0.0001 for IFNc and median 23 v 42 pg/ml, p = 0.044 for IL4) (figs 1A and B).
In patients with RA the IFNc secretion of PBMC had already increased after 2 weeks of treatment (median 1513 v 10 780 pg/ml, p = 0.001) and increased further between 2 and 6 weeks (median 10 780 v 14 190 pg/ml, p = 0.022) ( fig 1A) . The IFNc and IL4 secretion of PHA stimulated PBMC increased also in the patients with other arthritides during the first 2 weeks of treatment (median 3753 v 4473 pg/ml, p = 0.043 for IFNc and median 27 v 54 pg/ml, p = 0.043 for IL4).
No differences during the 6 weeks' follow up were seen in the concentration of PHA stimulated IL5 or TNFa secretion by PBMC from patients with infliximab treatment (data not shown). No differences in the PHA stimulated cytokine secretion of PBMC were found in healthy controls in the samples taken 2 weeks apart (data not shown).
The ratio of IFNc/IL4 mRNA in PHA stimulated PBMC increased during treatment in both patient groups. An increase between 0 and 6 weeks was significant in patients with RA (median 0.2 v 1.5, range 0-13 before treatment and 0-15 6 weeks after, p,0.0001) and for patients with other arthritides (median 0.1 v 1.0, range 0-0.3 before treatment and 1-2 6 weeks after, p = 0.043). No changes were seen in the control subjects.
In patients with RA the TNFa mRNA levels increased during treatment, the increase between 2 and 6 weeks being significant (median 260 v 752, range 0-2784 at 2 weeks and range 86-2784 at 6 weeks, p = 0.009). No changes in the TNFa mRNA levels were seen in patients with other arthritides or in healthy controls (data not shown).
Chemokine receptor profile during infliximab treatment
In patients with RA the number of CD4 T cells and CD14 monocytes expressing CCR3 increased during treatment. The number of CD4 T cells expressing CCR3 increased between 0 and 2 weeks (median 0.4 v 0.8, p = 0.028) and between 0 and 6 weeks (median 0.4 v 0.6, p = 0.013) (fig 2A) . The number of CD14 monocytes expressing CCR3 increased between 0 and 6 weeks (median 0.9 v 2.4, p = 0.009) (fig 2B) . No changes in the expression of CCR3 on CD8 T cells were seen during the follow up period in patients with RA.
In patients with RA the expression of CCR5 on CD8 T cells increased during the treatment, the increase between 2 and 6 weeks being significant (median 0.13 v 0.2, p = 0.040) (fig 2C) . No changes were seen in the expression of CCR5 on CD4 T cells or monocytes during the follow up period.
In patients with other arthritides no changes in the expression of CCR5 or CCR3 on T cells or monocytes was seen during the follow up period. In healthy controls the expression of CCR5 on monocytes decreased during the 2 week follow up (median 0.7 v 1.0, range 0-2 at 0 weeks and range 0-1 at 2 weeks, p = 0.017).
Markers associated with responsiveness to the treatment The effect of treatment was determined at 2 weeks' follow up before the second infusion of TNFa blocking agent.
The number of CD8 T cells expressing CCR3 was higher before the start of treatment in non-responders than in responders (median 0.3 v 0.1, p = 0.022) ( fig 3A) .
The number of CD4 T cells expressing CCR3 and CCR5 was higher in patients not responding to treatment than in the responders throughout the follow up period. The difference between non-responders and responders was significant before the start of treatment for CCR5 (median 0.2 v 0.1, p = 0.013) ( fig 3B) and after 6 weeks of treatment for CCR3 and CCR5 (median 1.5 v 0.3, p = 0.020 and median 0.3 v 0.1, p = 0.029, respectively). Also before the start of treatment a similar trend was seen for CCR3 (median 0.5 v 0.3, p = 0.053) ( fig 3C) .
In patients with RA the number of CD3 T cells increased in patients responding to treatment and such a change was not seen in non-responders. When the change in the number of CD3 T cells during treatment was compared, the responders and non-responders differed (p = 0.001) ( figs 4A and B) . No significant differences in other immunological measures between responders and non-responders were seen (data not shown).
DISCUSSION
At entry, the patients with RA showed impaired cytokine secretion of PBMC in response to PHA stimulation in comparison with controls, suggesting decreased peripheral T cell function as reported earlier. [16] [17] [18] The TNFa blockade normalised the mitogen response of PBMC as shown by the normal production of both IFNc and IL4. Activation of type 1 immune response, described as an increase in the number of PBMC spontaneously producing IFNc after 4 weeks of treatment with etanercept, a soluble TNF receptor, has been reported earlier by Berg et al.
11 Also IFNc production of PBMC stimulated with microbial antigens (purified protein derivative, influenza virus) or autoantigen (collagen type II) increased in the patients during treatment. No increase in the mitogen stimulated IFNc production was found, but instead, an increase in the secretion of IL2 was seen. Increased secretion of IL2 and IFNc has also been reported in patients with spondyloarthropathy receiving infliximab. 19 As a conclusion, these studies together with our study suggest that recovery of impaired Th1 response is associated with TNFa blocking. In our study we also found an increase in the type 2 associated cytokine secretion after PHA stimulation in patients receiving infliximab. However, our observation of an increase in the IFNc/IL4 mRNA ratio, stimulated by PHA, suggests a more pronounced effect on type 1 immunity.
It has been reported that the chronic overproduction of TNFa suppresses T cell functions, 20 and thus elimination of excess TNFa in patients receiving TNFa blocking agent results in recovery of T cell responses. These findings of enhanced Th1 immunity as a response to TNFa blocking challenge the paradigm of pathogenicity of Th1 cells in RA, as discussed also in the context of spondyloarthropathy. 19 Possibly, the recovery of T cell function is associated with the recovery of regulatory mechanisms, and the impaired peripheral T cell function may fundamentally be associated with autoimmunity.
We found that the number of T cells and monocytes expressing CCR3 and CCR5 increased as response to treatment in patients with RA. This indicates activation of peripheral T cells and is in accordance with the increase in the mitogen stimulated cytokine response observed. It is also possible that the increase in the number of CCR3 and CCR5 expressing cells reflects the decreased accumulation of inflammatory cells from the periphery to inflamed joints, as suggested previously. 7 In patients with other arthritides we found no change in the expression of chemokine receptors during treatment. This might be due to the small number and heterogeneous disease pattern among the patients studied.
It has been reported that TNFa decreases expression of CCR5 in peripheral blood monocytes and alveolar macrophages by production of the CCR5 ligand, RANTES. 21 Down regulation of CCR5 as a response to TNFa is detected also on dendritic cells. 22 23 Hornung et al reported that TNFa affects CCR5 expression on peripheral blood lymphocytes. 24 They showed that TNFa down regulates the expression of CCR5 on previously activated peripheral blood lymphocytes and delays the expression of CCR5 on the cells early in the activation process. Also, CCR3 is down regulated by TNFa as shown by Sato et al. 25 Thus, the increase in CCR3 and CCR5 expression on T cells and monocytes can be explained by a rebound effect due to blocking of TNFa.
When patients with RA were divided into responding and non-responding groups according to ACR20 criteria, the patients responding to treatment had a lower numbers of T cells expressing CCR3 and CCR5 before the start of infusions than the non-responders. High levels of CCR3 and CCR5 on CD4 and on CD8 positive T cells were thus predictive markers of a poor effect of treatment. This suggests that the activation of peripheral T cells is an important mechanisms in TNFa blocking and, possibly, this treatment is most effective in those patients with impaired peripheral T cell function, because the excess TNFa also causes down regulation of chemokine receptors. The high levels of CCR3 and CCR5 on the T cells of patients not responding to infliximab might indicate that in these patients the activity of RA is more dependent on other inflammatory mediators and less on TNFa.
It has been reported that patients with RA have a greater number of TNFa-producing PBMC both before and after treatment with TNFa blocking agents than healthy controls, and no effect on the number cells spontaneously producing TNFa during TNFa treatment is seen. 11 In our study treatment increased the expression of TNFa at the mRNA level, probably owing to positive feedback mechanisms, but no effect at the protein level was seen as PHA stimulated secretion of TNFa did not change during treatment in patients with RA.
Some reports show that the number of circulating lymphocytes is transiently increased after monoclonal antiTNFa antibody treatment in a dose dependent fashion. 26 In response to treatment, the number of T cells increased and the CRP levels decreased in the patients who showed good clinical response in our study, but no changes in T cells were seen in the patient group as a whole. Our results suggest that changes in T cell number and CRP are related to the effect of treatment.
In conclusion, the TNFa blocking treatment seems to activate the cell mediated immune system to compensate or to rebalance itself. Increase in the induced production of both type 1 and type 2 cytokines, together with the increase in the number of T cells and monocytes expressing CCR3 and CCR5, suggest that recovery of peripheral T cell function is associated with the clinical effects of TNFa blocking. This treatment seems to be most effective among those patients with RA who have decreased expression of chemokine receptors on peripheral T cells before the start of treatment.
